30 Day Trial

NuVasive Reports 2Q16 Revenue

Share:

NuVasive reported 2Q16 revenue of US $236.2MM, +16.4% from 2Q15. (U.S. $200.5MM, +12.7%; ex-U.S. $35.6MM, +43.6%) All growth is as reported.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.